A novel model mouth system for evaluation of In Vitro release of nicotine from moist snuff

Chemistry Central Journal

Yong-Li Zong²  Jian-Ping Xie²  Shi-Hao Sun²  Jie Zhang¹  Peng Li² 

[1]Beijing Workstation of Technology Centre of Shanghai Tobacco (Group) Corporation, Beijing 101121, China

[2]Zhengzhou Tobacco Research Institute of China National Tobacco Corporation, Zhengzhou 450001, China

关键词: Smokeless tobacco products;    Moist snuff;    Release;    In vitro;    Nicotine;    Model mouth system;   

Others  :  787818
DOI  :  10.1186/1752-153X-7-176

 received in 2013-04-27, accepted in 2013-11-06,  发布年份 2013

【 摘 要 】

Background

Pouch moist snuff, as a form of oral smokeless tobacco products, is becoming increasingly popular in North America, Scandinavia (where it is known as Snus), South Asia and parts of Africa. User usually places a pouch between the upper jaw and cheek to obtain euphoria from tobacco, leading to partial intake of tobacco constituents. To evaluate user exposure to tobacco, an approach with a novel model mouth system was developed and applied to evaluate release of nicotine from the pouch.

Results

A novel model mouth system has been developed to evaluate release behavior of tobacco constituents in pouch moist snuff. The system consists of the release medium reservoir module, the flow speed control module, the temperature control module, nicotine release module, and release solution collection module, and simulates buccal condition in terms of temperature, saliva compositions, and the rate of saliva production, etc. Artificial saliva was used as the release medium to evaluate release of nicotine in pouch moist snuff. The optimized test condition was that the release temperature of 37°C and the flow rate performed at 0.2 mL min-1 in the first 5 min and 0.1 mL min-1 in the next 55 min. The performance of the model mouth system was compared with in vivo data of nicotine release in human volunteers. Data from 23 brands of moist snuff indicated that nicotine release rates increased with extraction time and approximately 60-90% of nicotine was released after 30 min of extraction in most of the samples, and the release behavior of nicotine was affected by product weights, nicotine concentration, and product pH, etc.

Conclusion

The model mouth system can be used to evaluate the release behavior of constituents in pouch moist snuff, especially those directly related to human health such as nicotine and tobacco specific nitrosamine (TSNA), etc. This indicated that the system is an alternative tool to evaluate user exposure to tobacco. With further testing and validation, the model mouth system can be applied in risk evaluation of smokeless tobacco products.

【 授权许可】

   
2013 Li et al.; licensee Chemistry Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]International Agency for Research on Cancer (IARC): Monographs on the evaluation of carcinogenic risk to humans volume 89: smokeless tobacco and some tobacco-specific nitrosa mines. Lyon: World Health Organization; 2007.
• [2]Alpert HR, Koh H, Connolly GN: Free nicotine content and strategic marketing of moist snuff tobacco products in the United States: 2000–2006. Tob Control 2008, 17:332-338.
• [3]Benowitz NL, Hukkanen J, Jacob P: Nicotine Psychopharmacology. Heidelberg: Springer-Verlag Berlin; 2009:29-60.
• [4]Benowitz NL: Nicotine and smokeless tobacco. CA: A Cancer J Clin 1988, 38:244-247.
• [5]Henningfield JE, Keenan RM: Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 1993, 61:743-750.
• [6]Yatsuya H, Folsom AR, Investigators A: Risk of incident cardiovascular disease among users of smokeless tobacco in the atherosclerosis risk in communities (ARIC) study. Am J Epidemiol 2010, 172:600-605.
• [7]Fant RV, Henningfield JE, Nelson RA, Pickworth WB: Pharmacokinetics and pharmacodynamics of moist snuff in humans. Tob Control 1999, 8:387-392.
• [8]Henningfield JE, Radzius A, Cone EJ: Estimation of available nicotine content of six smokeless tobacco products. Tob Control 1995, 4:57-61.
• [9]Luque-Perez E, Rios A, Valcarcel M, Danielsson LG, Ingman F: Analysis of solid samples using supported liquid membranes: a method for the evaluation of the release of nicotine from Swedish snuff. Anal Chim Acta 1999, 387:155-164.
• [10]Nasr MM, Reepmeyer JC, Yubing T: In vitro study of nicotine release from smokeless tobacco. J AOAC Int 1998, 81:540-543.
• [11]Genovese A, Piombino P, Gambuti A, Moio L: Simulation of retronasal aroma of white and red wine in a model mouth system. investigating the influence of saliva on volatile compound concentrations. Food Chem 2009, 114:100-107.
• [12]Deibler KD, Lavin EH, Linforth RST, Taylor AJ, Acree TE: Verification of a mouth simulator by in vivo measurements. J Agric Food Chem 2001, 49:1388-1393.
• [13]Piggott JR, Schaschke CJ: Released cells, breath analysis and in-mouth analysis in flavour research. Biomol Eng 2001, 17:129-136.
• [14]Ciolino LA, McCauley HA, Fraser DB, Wolnik KA: The relative buffering capacities of saliva and moist snuff: implications for nicotine absorption. J Anal Toxicol 2001, 25:15-25.
• [15]Munasur AP, Pillay V, Choonara YE, Mackraj I, Govender T: Comparing the mucoadhesivity and drug release mechanisms of various polymer-containing propranolol buccal tablets. Drug Dev Ind Pharm 2008, 34:189-198.
• [16]Akbari J, Nokhodchi A, Farid D, Adrangui M, Siahi-Shadbad MR, Saeedi M: Development and evaluation of buccoadhesive propranolol hydrochloride tablet formulations: effect of fillers. Il Farmaco 2004, 59:155-161.
• [17]Giunchedi P, Juliano C, Gavini E, Cossu M, Sorrenti M: Formulation and in vivo evaluation of chlorhexidine buccal tablets prepared using drug-loaded chitosan microspheres. Eur J Pharm Biopharm 2002, 53:233-239.
• [18]Chou CC, Hee SSQ: Bioassay-driven analysis of chewing tobacco extracts. Environ Toxicol Chem 1994, 13:1177-1186.
• [19]CORESTA Recommended Methods No.69: Determination of pH in smokeless tobacco products. http://www.coresta.org/Recommended_Methods/CRM_69.pdf webcite
• [20]ICH, Guidance for Industry: Q2B Validation of Analytical Procedures. Methodology; http://www.fda.gov/cder/guidance/index.htm webcite
• [21]Izutsu KT: Theory and measurement of the buffer value of bicarbonate in saliva. J Theoretical Biol 1981, 90:397-403.
• [22]Dilena BA, Walmsley RN, Fraser CG: Total and ionized calcium in plasma and saliva. Clin Chem 1983, 29:1856-1857.
• [23]Lunell E, Lunell M: Steady-state nicotine plasma levels following use of four different types of Swedish snus compared with 2-mg nicorette chewing gum: a crossover study. Nicotine Tob Res 2005, 7:397-403.
• [24]Lunell E, Curvall M: Nicotine delivery and subjective effects of Swedish portion snus compared with 4 mg nicotine polacrilex chewing gum. Nicotine Tob Res 2011, 13:573-578.
• [25]Caraway JW, Chen PX: Assessment of mouth-level exposure to tobacco constituents in U.S. snus consumers. Nicotine Tob Res 2013, 15:670-677.
• [26]Digard H, Proctor C, Kulasekaran A, Malmqvist U, Richter A: Determination of nicotine absorption from multiple tobacco products and nicotine gum. Nicotine Tob Res 2013, 15:255-261.
• [27]Digard H, Gale N, Errington G, Peters N, McAdam K: Multi-analyte approach for determining the extraction of tobacco constituents from pouched snus by consumers during use. Chem Centr J 2013. doi:10.1186/1752-153X-7-55